Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Neurodegenerative Disorder Therapeutics market report explains the definition, types, applications, major countries, and major players of the Neurodegenerative Disorder Therapeutics market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
Teva Pharmaceutical Industries Ltd
AbbVie Inc
Merck KGaA
Bayer AG
Novartis AG
Bristol Myers Squibb Company
Biogen Inc
Boehringer Ingeiheim International GmbH
GlaxoSmithKline PLC
Eisai CO LTD
Pfizer Inc
F Hoffmann- La Roche Ltd
Sanofi SA
H Lundbeck
UCB SA
By Type:
Immunomodulators
Interferons
Decarboxylase Inhibitors
Dopamine Agonists
Others
By End-User:
Multiple Sclerosis
Parkinson'S Disease
Alzheimer'S Disease
Spinal Muscular Atrophy
Huntington Disease
Other Neurodegenerative Disorders
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Neurodegenerative Disorder Therapeutics Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Neurodegenerative Disorder Therapeutics Outlook to 2028- Original Forecasts
-
2.2 Neurodegenerative Disorder Therapeutics Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Neurodegenerative Disorder Therapeutics Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Neurodegenerative Disorder Therapeutics Market- Recent Developments
-
6.1 Neurodegenerative Disorder Therapeutics Market News and Developments
-
6.2 Neurodegenerative Disorder Therapeutics Market Deals Landscape
7 Neurodegenerative Disorder Therapeutics Raw Materials and Cost Structure Analysis
-
7.1 Neurodegenerative Disorder Therapeutics Key Raw Materials
-
7.2 Neurodegenerative Disorder Therapeutics Price Trend of Key Raw Materials
-
7.3 Neurodegenerative Disorder Therapeutics Key Suppliers of Raw Materials
-
7.4 Neurodegenerative Disorder Therapeutics Market Concentration Rate of Raw Materials
-
7.5 Neurodegenerative Disorder Therapeutics Cost Structure Analysis
-
7.5.1 Neurodegenerative Disorder Therapeutics Raw Materials Analysis
-
7.5.2 Neurodegenerative Disorder Therapeutics Labor Cost Analysis
-
7.5.3 Neurodegenerative Disorder Therapeutics Manufacturing Expenses Analysis
8 Global Neurodegenerative Disorder Therapeutics Import and Export Analysis (Top 10 Countries)
-
8.1 Global Neurodegenerative Disorder Therapeutics Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Neurodegenerative Disorder Therapeutics Export by Region (Top 10 Countries) (2017-2028)
9 Global Neurodegenerative Disorder Therapeutics Market Outlook by Types and Applications to 2022
-
9.1 Global Neurodegenerative Disorder Therapeutics Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Immunomodulators Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Interferons Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Decarboxylase Inhibitors Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Dopamine Agonists Consumption and Growth Rate (2017-2022)
-
9.1.5 Global Others Consumption and Growth Rate (2017-2022)
-
9.2 Global Neurodegenerative Disorder Therapeutics Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Multiple Sclerosis Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Parkinson'S Disease Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Alzheimer'S Disease Consumption and Growth Rate (2017-2022)
-
9.2.4 Global Spinal Muscular Atrophy Consumption and Growth Rate (2017-2022)
-
9.2.5 Global Huntington Disease Consumption and Growth Rate (2017-2022)
-
9.2.6 Global Other Neurodegenerative Disorders Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Neurodegenerative Disorder Therapeutics Market Analysis and Outlook till 2022
-
10.1 Global Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.2.2 Canada Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.2.3 Mexico Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.3.2 UK Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.3.3 Spain Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.3.4 Belgium Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.3.5 France Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.3.6 Italy Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.3.7 Denmark Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.3.8 Finland Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.3.9 Norway Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.3.10 Sweden Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.3.11 Poland Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.3.12 Russia Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.3.13 Turkey Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.4.2 Japan Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.4.3 India Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.4.4 South Korea Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.4.5 Pakistan Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.4.6 Bangladesh Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.4.7 Indonesia Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.4.8 Thailand Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.4.9 Singapore Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.4.10 Malaysia Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.4.11 Philippines Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.4.12 Vietnam Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.5.2 Colombia Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.5.3 Chile Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.5.4 Argentina Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.5.5 Venezuela Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.5.6 Peru Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.5.7 Puerto Rico Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.5.8 Ecuador Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.6.2 Kuwait Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.6.3 Oman Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.6.4 Qatar Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.6.5 Saudi Arabia Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.6.6 United Arab Emirates Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.7.2 South Africa Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.7.3 Egypt Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.7.4 Algeria Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
-
10.8.2 New Zealand Neurodegenerative Disorder Therapeutics Consumption (2017-2022)
11 Global Neurodegenerative Disorder Therapeutics Competitive Analysis
-
11.1 Teva Pharmaceutical Industries Ltd
-
11.1.1 Teva Pharmaceutical Industries Ltd Company Details
-
11.1.2 Teva Pharmaceutical Industries Ltd Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 Teva Pharmaceutical Industries Ltd Neurodegenerative Disorder Therapeutics Main Business and Markets Served
-
11.1.4 Teva Pharmaceutical Industries Ltd Neurodegenerative Disorder Therapeutics Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 AbbVie Inc
-
11.2.1 AbbVie Inc Company Details
-
11.2.2 AbbVie Inc Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 AbbVie Inc Neurodegenerative Disorder Therapeutics Main Business and Markets Served
-
11.2.4 AbbVie Inc Neurodegenerative Disorder Therapeutics Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 Merck KGaA
-
11.3.1 Merck KGaA Company Details
-
11.3.2 Merck KGaA Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 Merck KGaA Neurodegenerative Disorder Therapeutics Main Business and Markets Served
-
11.3.4 Merck KGaA Neurodegenerative Disorder Therapeutics Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 Bayer AG
-
11.4.1 Bayer AG Company Details
-
11.4.2 Bayer AG Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 Bayer AG Neurodegenerative Disorder Therapeutics Main Business and Markets Served
-
11.4.4 Bayer AG Neurodegenerative Disorder Therapeutics Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 Novartis AG
-
11.5.1 Novartis AG Company Details
-
11.5.2 Novartis AG Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 Novartis AG Neurodegenerative Disorder Therapeutics Main Business and Markets Served
-
11.5.4 Novartis AG Neurodegenerative Disorder Therapeutics Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 Bristol Myers Squibb Company
-
11.6.1 Bristol Myers Squibb Company Company Details
-
11.6.2 Bristol Myers Squibb Company Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 Bristol Myers Squibb Company Neurodegenerative Disorder Therapeutics Main Business and Markets Served
-
11.6.4 Bristol Myers Squibb Company Neurodegenerative Disorder Therapeutics Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 Biogen Inc
-
11.7.1 Biogen Inc Company Details
-
11.7.2 Biogen Inc Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 Biogen Inc Neurodegenerative Disorder Therapeutics Main Business and Markets Served
-
11.7.4 Biogen Inc Neurodegenerative Disorder Therapeutics Product Portfolio
-
11.7.5 Recent Research and Development Strategies
-
11.8 Boehringer Ingeiheim International GmbH
-
11.8.1 Boehringer Ingeiheim International GmbH Company Details
-
11.8.2 Boehringer Ingeiheim International GmbH Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.8.3 Boehringer Ingeiheim International GmbH Neurodegenerative Disorder Therapeutics Main Business and Markets Served
-
11.8.4 Boehringer Ingeiheim International GmbH Neurodegenerative Disorder Therapeutics Product Portfolio
-
11.8.5 Recent Research and Development Strategies
-
11.9 GlaxoSmithKline PLC
-
11.9.1 GlaxoSmithKline PLC Company Details
-
11.9.2 GlaxoSmithKline PLC Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.9.3 GlaxoSmithKline PLC Neurodegenerative Disorder Therapeutics Main Business and Markets Served
-
11.9.4 GlaxoSmithKline PLC Neurodegenerative Disorder Therapeutics Product Portfolio
-
11.9.5 Recent Research and Development Strategies
-
11.10 Eisai CO LTD
-
11.10.1 Eisai CO LTD Company Details
-
11.10.2 Eisai CO LTD Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.10.3 Eisai CO LTD Neurodegenerative Disorder Therapeutics Main Business and Markets Served
-
11.10.4 Eisai CO LTD Neurodegenerative Disorder Therapeutics Product Portfolio
-
11.10.5 Recent Research and Development Strategies
-
11.11 Pfizer Inc
-
11.11.1 Pfizer Inc Company Details
-
11.11.2 Pfizer Inc Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.11.3 Pfizer Inc Neurodegenerative Disorder Therapeutics Main Business and Markets Served
-
11.11.4 Pfizer Inc Neurodegenerative Disorder Therapeutics Product Portfolio
-
11.11.5 Recent Research and Development Strategies
-
11.12 F Hoffmann- La Roche Ltd
-
11.12.1 F Hoffmann- La Roche Ltd Company Details
-
11.12.2 F Hoffmann- La Roche Ltd Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.12.3 F Hoffmann- La Roche Ltd Neurodegenerative Disorder Therapeutics Main Business and Markets Served
-
11.12.4 F Hoffmann- La Roche Ltd Neurodegenerative Disorder Therapeutics Product Portfolio
-
11.12.5 Recent Research and Development Strategies
-
11.13 Sanofi SA
-
11.13.1 Sanofi SA Company Details
-
11.13.2 Sanofi SA Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.13.3 Sanofi SA Neurodegenerative Disorder Therapeutics Main Business and Markets Served
-
11.13.4 Sanofi SA Neurodegenerative Disorder Therapeutics Product Portfolio
-
11.13.5 Recent Research and Development Strategies
-
11.14 H Lundbeck
-
11.14.1 H Lundbeck Company Details
-
11.14.2 H Lundbeck Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.14.3 H Lundbeck Neurodegenerative Disorder Therapeutics Main Business and Markets Served
-
11.14.4 H Lundbeck Neurodegenerative Disorder Therapeutics Product Portfolio
-
11.14.5 Recent Research and Development Strategies
-
11.15 UCB SA
-
11.15.1 UCB SA Company Details
-
11.15.2 UCB SA Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.15.3 UCB SA Neurodegenerative Disorder Therapeutics Main Business and Markets Served
-
11.15.4 UCB SA Neurodegenerative Disorder Therapeutics Product Portfolio
-
11.15.5 Recent Research and Development Strategies
12 Global Neurodegenerative Disorder Therapeutics Market Outlook by Types and Applications to 2028
-
12.1 Global Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global Immunomodulators Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global Interferons Consumption Forecast and Growth Rate (2022-2028)
-
12.1.3 Global Decarboxylase Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
12.1.4 Global Dopamine Agonists Consumption Forecast and Growth Rate (2022-2028)
-
12.1.5 Global Others Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Multiple Sclerosis Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Parkinson'S Disease Consumption Forecast and Growth Rate (2022-2028)
-
12.2.3 Global Alzheimer'S Disease Consumption Forecast and Growth Rate (2022-2028)
-
12.2.4 Global Spinal Muscular Atrophy Consumption Forecast and Growth Rate (2022-2028)
-
12.2.5 Global Huntington Disease Consumption Forecast and Growth Rate (2022-2028)
-
12.2.6 Global Other Neurodegenerative Disorders Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Neurodegenerative Disorder Therapeutics Market Analysis and Outlook to 2028
-
13.1 Global Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.2.2 Canada Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.2.3 Mexico Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.3.2 UK Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.3.3 Spain Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.3.4 Belgium Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.3.5 France Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.3.6 Italy Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.3.7 Denmark Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.3.8 Finland Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.3.9 Norway Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.3.10 Sweden Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.3.11 Poland Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.3.12 Russia Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.3.13 Turkey Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.4.2 Japan Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.4.3 India Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.4.4 South Korea Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.4.8 Thailand Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.4.9 Singapore Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.4.11 Philippines Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.5.2 Colombia Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.5.3 Chile Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.5.4 Argentina Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.5.6 Peru Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.6.3 Oman Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.6.4 Qatar Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.7.2 South Africa Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.7.3 Egypt Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.7.4 Algeria Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Neurodegenerative Disorder Therapeutics Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Neurodegenerative Disorder Therapeutics
-
Figure of Neurodegenerative Disorder Therapeutics Picture
-
Table Global Neurodegenerative Disorder Therapeutics Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Neurodegenerative Disorder Therapeutics Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global Immunomodulators Consumption and Growth Rate (2017-2022)
-
Figure Global Interferons Consumption and Growth Rate (2017-2022)
-
Figure Global Decarboxylase Inhibitors Consumption and Growth Rate (2017-2022)
-
Figure Global Dopamine Agonists Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Multiple Sclerosis Consumption and Growth Rate (2017-2022)
-
Figure Global Parkinson'S Disease Consumption and Growth Rate (2017-2022)
-
Figure Global Alzheimer'S Disease Consumption and Growth Rate (2017-2022)
-
Figure Global Spinal Muscular Atrophy Consumption and Growth Rate (2017-2022)
-
Figure Global Huntington Disease Consumption and Growth Rate (2017-2022)
-
Figure Global Other Neurodegenerative Disorders Consumption and Growth Rate (2017-2022)
-
Figure Global Neurodegenerative Disorder Therapeutics Consumption by Country (2017-2022)
-
Table North America Neurodegenerative Disorder Therapeutics Consumption by Country (2017-2022)
-
Figure United States Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Canada Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Mexico Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Table Europe Neurodegenerative Disorder Therapeutics Consumption by Country (2017-2022)
-
Figure Germany Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure UK Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Spain Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Belgium Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure France Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Italy Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Denmark Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Finland Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Norway Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Sweden Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Poland Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Russia Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Turkey Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Table APAC Neurodegenerative Disorder Therapeutics Consumption by Country (2017-2022)
-
Figure China Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Japan Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure India Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure South Korea Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Thailand Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Singapore Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Philippines Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Table South America Neurodegenerative Disorder Therapeutics Consumption by Country (2017-2022)
-
Figure Brazil Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Colombia Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Chile Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Argentina Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Peru Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Table GCC Neurodegenerative Disorder Therapeutics Consumption by Country (2017-2022)
-
Figure Bahrain Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Oman Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Qatar Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Table Africa Neurodegenerative Disorder Therapeutics Consumption by Country (2017-2022)
-
Figure Nigeria Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure South Africa Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Egypt Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Algeria Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Table Oceania Neurodegenerative Disorder Therapeutics Consumption by Country (2017-2022)
-
Figure Australia Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Neurodegenerative Disorder Therapeutics Consumption and Growth Rate (2017-2022)
-
Table Teva Pharmaceutical Industries Ltd Company Details
-
Table Teva Pharmaceutical Industries Ltd Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Teva Pharmaceutical Industries Ltd Neurodegenerative Disorder Therapeutics Main Business and Markets Served
-
Table Teva Pharmaceutical Industries Ltd Neurodegenerative Disorder Therapeutics Product Portfolio
-
Table AbbVie Inc Company Details
-
Table AbbVie Inc Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table AbbVie Inc Neurodegenerative Disorder Therapeutics Main Business and Markets Served
-
Table AbbVie Inc Neurodegenerative Disorder Therapeutics Product Portfolio
-
Table Merck KGaA Company Details
-
Table Merck KGaA Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Merck KGaA Neurodegenerative Disorder Therapeutics Main Business and Markets Served
-
Table Merck KGaA Neurodegenerative Disorder Therapeutics Product Portfolio
-
Table Bayer AG Company Details
-
Table Bayer AG Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bayer AG Neurodegenerative Disorder Therapeutics Main Business and Markets Served
-
Table Bayer AG Neurodegenerative Disorder Therapeutics Product Portfolio
-
Table Novartis AG Company Details
-
Table Novartis AG Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novartis AG Neurodegenerative Disorder Therapeutics Main Business and Markets Served
-
Table Novartis AG Neurodegenerative Disorder Therapeutics Product Portfolio
-
Table Bristol Myers Squibb Company Company Details
-
Table Bristol Myers Squibb Company Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bristol Myers Squibb Company Neurodegenerative Disorder Therapeutics Main Business and Markets Served
-
Table Bristol Myers Squibb Company Neurodegenerative Disorder Therapeutics Product Portfolio
-
Table Biogen Inc Company Details
-
Table Biogen Inc Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Biogen Inc Neurodegenerative Disorder Therapeutics Main Business and Markets Served
-
Table Biogen Inc Neurodegenerative Disorder Therapeutics Product Portfolio
-
Table Boehringer Ingeiheim International GmbH Company Details
-
Table Boehringer Ingeiheim International GmbH Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Boehringer Ingeiheim International GmbH Neurodegenerative Disorder Therapeutics Main Business and Markets Served
-
Table Boehringer Ingeiheim International GmbH Neurodegenerative Disorder Therapeutics Product Portfolio
-
Table GlaxoSmithKline PLC Company Details
-
Table GlaxoSmithKline PLC Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table GlaxoSmithKline PLC Neurodegenerative Disorder Therapeutics Main Business and Markets Served
-
Table GlaxoSmithKline PLC Neurodegenerative Disorder Therapeutics Product Portfolio
-
Table Eisai CO LTD Company Details
-
Table Eisai CO LTD Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Eisai CO LTD Neurodegenerative Disorder Therapeutics Main Business and Markets Served
-
Table Eisai CO LTD Neurodegenerative Disorder Therapeutics Product Portfolio
-
Table Pfizer Inc Company Details
-
Table Pfizer Inc Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pfizer Inc Neurodegenerative Disorder Therapeutics Main Business and Markets Served
-
Table Pfizer Inc Neurodegenerative Disorder Therapeutics Product Portfolio
-
Table F Hoffmann- La Roche Ltd Company Details
-
Table F Hoffmann- La Roche Ltd Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table F Hoffmann- La Roche Ltd Neurodegenerative Disorder Therapeutics Main Business and Markets Served
-
Table F Hoffmann- La Roche Ltd Neurodegenerative Disorder Therapeutics Product Portfolio
-
Table Sanofi SA Company Details
-
Table Sanofi SA Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Sanofi SA Neurodegenerative Disorder Therapeutics Main Business and Markets Served
-
Table Sanofi SA Neurodegenerative Disorder Therapeutics Product Portfolio
-
Table H Lundbeck Company Details
-
Table H Lundbeck Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table H Lundbeck Neurodegenerative Disorder Therapeutics Main Business and Markets Served
-
Table H Lundbeck Neurodegenerative Disorder Therapeutics Product Portfolio
-
Table UCB SA Company Details
-
Table UCB SA Neurodegenerative Disorder Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table UCB SA Neurodegenerative Disorder Therapeutics Main Business and Markets Served
-
Table UCB SA Neurodegenerative Disorder Therapeutics Product Portfolio
-
Figure Global Immunomodulators Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Interferons Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Decarboxylase Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Dopamine Agonists Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Multiple Sclerosis Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Parkinson'S Disease Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Alzheimer'S Disease Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Spinal Muscular Atrophy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Huntington Disease Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Other Neurodegenerative Disorders Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Neurodegenerative Disorder Therapeutics Consumption Forecast by Country (2022-2028)
-
Table North America Neurodegenerative Disorder Therapeutics Consumption Forecast by Country (2022-2028)
-
Figure United States Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Neurodegenerative Disorder Therapeutics Consumption Forecast by Country (2022-2028)
-
Figure Germany Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Neurodegenerative Disorder Therapeutics Consumption Forecast by Country (2022-2028)
-
Figure China Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Neurodegenerative Disorder Therapeutics Consumption Forecast by Country (2022-2028)
-
Figure Brazil Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Neurodegenerative Disorder Therapeutics Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Neurodegenerative Disorder Therapeutics Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Neurodegenerative Disorder Therapeutics Consumption Forecast by Country (2022-2028)
-
Figure Australia Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Neurodegenerative Disorder Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
